• NovaBridge Biosciences President, Chief Commercial Officer Mark Arnold Hagler reported a purchase of 230,000 ordinary shares at USD 2.51 per share.
• Beneficial ownership stood at 230,000 ordinary shares following transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-186924), on April 28, 2026, and is solely responsible for the information contained therein.